Previous studies have shown that the inhibition of STAT3 Y705 tyrosine phosphorylation, mainly mediated by Janus activating kinases (JAK) 2, may be an effective strategy for reducing the survival of PEL cells [5,6]. Here, JAK2 is linked to primary effusion lymphoma.